Product Pathways - Growth Factors/Cytokines
Human Erythropoietin (hEPO) #6980
|6980LF||50 µg (Carrier Free)||---||In Stock||---|
|6980LC||50 µg (With Carrier)||---||In Stock||---|
|6980SC||10 µg (With Carrier)||---||In Stock||---|
|6980SF||10 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant human Erythropoietin (hEPO) Ala28-Arg193 (Accession #NP_000790) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant hEPO contains no "tags" and the nonglycosylated protein has a calculated MW of 20,417. DTT-reduced and non-reduced protein migrate as 34-40 kDa polypeptides. Lower mobility in SDS-PAGE is due to glycosylation. The expected amino-terminal APPRL of recombinant hEPO was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hEPO. All lots are greater than 98% pure.
The bioactivity of recombinant hEPO was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 50-400 pg/ml.
The purity of recombinant hEPO was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hEPO and staining overnight with Coomassie Blue.
Less than 0.01 ng endotoxin/1μg hEPO.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hEPO. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
EPO is a 34 kDa protein that is required for the survival and terminal differentiation of erythrocytes (1). EPO is produced by a number of cell types including tubular endothelial cells, interstitial cells, hepatocytes, Kupffer cells, astrocytes, and Schwann cells (2-4). EPO inhibits apoptosis and may protect neuronal cells from death during ischemia and/or neurodegenerative diseases (3,4). EPO inhibits the production of pro-inflammatory cytokines through inhibition of NF-κB signaling (5). EPO protected against the development of diabetes in an animal model by promoting pancreatic β cell survival and growth (6). Binding of EPO to its cognate receptor, EPOR, induces activation of Jak2, Stat5 and Akt (3-5).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.